DD271108A5 - PROCESS FOR PREPARING AMINO-PROPANOL DERIVATIVES OF 3- (3-HYDROXYPHENYL) -1-PROPANONE COMPOUNDS AND THEIR SAEUREADDITIONAL SALTS - Google Patents
PROCESS FOR PREPARING AMINO-PROPANOL DERIVATIVES OF 3- (3-HYDROXYPHENYL) -1-PROPANONE COMPOUNDS AND THEIR SAEUREADDITIONAL SALTS Download PDFInfo
- Publication number
- DD271108A5 DD271108A5 DD88317034A DD31703488A DD271108A5 DD 271108 A5 DD271108 A5 DD 271108A5 DD 88317034 A DD88317034 A DD 88317034A DD 31703488 A DD31703488 A DD 31703488A DD 271108 A5 DD271108 A5 DD 271108A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- atoms
- hydroxy
- propanone
- phenyl
- methoxyphenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 150000003839 salts Chemical class 0.000 title claims description 25
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical class CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 title abstract description 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- LRMHFDNWKCSEQU-UHFFFAOYSA-N ethoxyethane;phenol Chemical compound CCOCC.OC1=CC=CC=C1 LRMHFDNWKCSEQU-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- AMQRNDIFPLIQBP-UHFFFAOYSA-N 3-(3-hydroxyphenyl)propanal Chemical class OC1=CC=CC(CCC=O)=C1 AMQRNDIFPLIQBP-UHFFFAOYSA-N 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract description 5
- -1 n-propylamino compound Chemical class 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000003288 anthiarrhythmic effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 5
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 206010036590 Premature baby Diseases 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 4
- 229960000203 propafenone Drugs 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- DZMULNWWBSJCIS-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-[3-(oxiran-2-ylmethoxy)phenyl]propan-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)CCC1=CC=CC(OCC2OC2)=C1 DZMULNWWBSJCIS-UHFFFAOYSA-N 0.000 description 2
- KPYOQGLZSGFUKM-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-[3-[2-hydroxy-3-(propan-2-ylamino)propoxy]-4-methoxyphenyl]propan-1-one;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C(=O)CCC1=CC=C(OC)C(OCC(O)CNC(C)C)=C1 KPYOQGLZSGFUKM-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- WFGPIFXWVUQVNB-UHFFFAOYSA-N 3-[3-[2-hydroxy-3-(propylamino)propoxy]-4-methoxyphenyl]-1-naphthalen-2-ylpropan-1-one;hydrochloride Chemical compound Cl.C1=C(OC)C(OCC(O)CNCCC)=CC(CCC(=O)C=2C=C3C=CC=CC3=CC=2)=C1 WFGPIFXWVUQVNB-UHFFFAOYSA-N 0.000 description 2
- XKZZMMKJVKWQGE-UHFFFAOYSA-N 3-[3-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1-(2,4,6-trimethylphenyl)propan-1-one;hydrochloride Chemical compound Cl.CC1=CC(C)=CC(C)=C1C(=O)CCC1=CC=CC(OCC(O)CNC(C)(C)C)=C1 XKZZMMKJVKWQGE-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YXCDDBXEROLCLE-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-[3-(2-hydroxy-3-morpholin-4-ylpropoxy)-4-methoxyphenyl]propan-1-one hydrochloride Chemical compound Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=C(C=C1)OC)OCC(CN1CCOCC1)O)=O YXCDDBXEROLCLE-UHFFFAOYSA-N 0.000 description 1
- WIYZLEZVKNGUOI-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-[3-(2-hydroxy-3-piperidin-1-ylpropoxy)phenyl]propan-1-one hydrochloride Chemical compound Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=CC=C1)OCC(CN1CCCCC1)O)=O WIYZLEZVKNGUOI-UHFFFAOYSA-N 0.000 description 1
- WAQXPJKUKOFBHK-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-[3-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propan-1-one hydrochloride Chemical compound Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=CC=C1)OCC(CNC(C)C)O)=O WAQXPJKUKOFBHK-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- AGIBHMPYXXPGAX-UHFFFAOYSA-N 2-(iodomethyl)oxirane Chemical compound ICC1CO1 AGIBHMPYXXPGAX-UHFFFAOYSA-N 0.000 description 1
- OSVOQDOCGKKCPJ-UHFFFAOYSA-N 2-[2-hydroxy-3-(2-methylbutan-2-ylamino)propoxy]-1,3-diphenylpropan-1-one Chemical compound C=1C=CC=CC=1C(=O)C(OCC(O)CNC(C)(C)CC)CC1=CC=CC=C1 OSVOQDOCGKKCPJ-UHFFFAOYSA-N 0.000 description 1
- GELMWIVBBPAMIO-UHFFFAOYSA-N 2-methylbutan-2-amine Chemical compound CCC(C)(C)N GELMWIVBBPAMIO-UHFFFAOYSA-N 0.000 description 1
- WHSMCMZFALLCCD-UHFFFAOYSA-N 3-(3-hydroxy-4-methoxyphenyl)-1-naphthalen-2-ylpropan-1-one Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C1=CC=C(C=CC=C2)C2=C1 WHSMCMZFALLCCD-UHFFFAOYSA-N 0.000 description 1
- DFLPEEAGRQDYGF-UHFFFAOYSA-N 3-(propylamino)propane-1,2-diol Chemical compound CCCNCC(O)CO DFLPEEAGRQDYGF-UHFFFAOYSA-N 0.000 description 1
- RHPPMSVWFMCSAL-UHFFFAOYSA-N 3-[3-(oxiran-2-ylmethoxy)phenyl]-1-phenanthren-3-ylpropan-1-one Chemical compound C=1C=C2C=CC3=CC=CC=C3C2=CC=1C(=O)CCC(C=1)=CC=CC=1OCC1CO1 RHPPMSVWFMCSAL-UHFFFAOYSA-N 0.000 description 1
- KZCVMVVMODIFOY-UHFFFAOYSA-N 3-[3-[2-hydroxy-3-(2-methylbutan-2-ylamino)propoxy]-4-methoxyphenyl]-1-phenylpropan-1-one Chemical compound C1(=CC=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)CC)O)=O KZCVMVVMODIFOY-UHFFFAOYSA-N 0.000 description 1
- CQQHJKXHXWGWAH-UHFFFAOYSA-N 3-[3-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]-1-(2,4,6-trimethylphenyl)propan-1-one Chemical compound CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=CC=C1)OCC(CNC(C)C)O)=O CQQHJKXHXWGWAH-UHFFFAOYSA-N 0.000 description 1
- AQTLDYIXFQDLNF-UHFFFAOYSA-N 3-[3-[2-hydroxy-3-(propylamino)propoxy]-4-methoxyphenyl]-1-(2-methoxyphenyl)propan-1-one hydrochloride Chemical compound Cl.COC1=C(C=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNCCC)O)=O AQTLDYIXFQDLNF-UHFFFAOYSA-N 0.000 description 1
- QXHUOMIOXFLLFZ-UHFFFAOYSA-N 3-[3-[3-(cyclohexylamino)-2-hydroxypropoxy]-4-methoxyphenyl]-1-(4-methylphenyl)propan-1-one hydrochloride Chemical compound Cl.CC1=CC=C(C=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC1CCCCC1)O)=O QXHUOMIOXFLLFZ-UHFFFAOYSA-N 0.000 description 1
- DGAXQAODMCBVEB-UHFFFAOYSA-N 3-[3-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-1-(3,4-dimethoxyphenyl)propan-1-one hydrochloride Chemical compound Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=CC=C1)OCC(CNC(C)(C)C)O)=O DGAXQAODMCBVEB-UHFFFAOYSA-N 0.000 description 1
- OWKVSPXNFHNZHA-UHFFFAOYSA-N 3-[4-methoxy-3-(oxiran-2-ylmethoxy)phenyl]-1-(4-methylphenyl)propan-1-one Chemical compound CC1=CC=C(C=C1)C(CCC1=CC(=C(C=C1)OC)OCC1CO1)=O OWKVSPXNFHNZHA-UHFFFAOYSA-N 0.000 description 1
- YUBVMXPANMVGBE-UHFFFAOYSA-N 3-[4-methoxy-3-(oxiran-2-ylmethoxy)phenyl]-1-naphthalen-2-ylpropan-1-one Chemical compound C1=C(C=CC2=CC=CC=C12)C(CCC1=CC(=C(C=C1)OC)OCC1CO1)=O YUBVMXPANMVGBE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- RGXFDHSTXMWMIT-UHFFFAOYSA-N C(C(=O)O)(=O)O.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=C(C=C1)OC)OCC(CNCCC)O)=O Chemical compound C(C(=O)O)(=O)O.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=C(C=C1)OC)OCC(CNCCC)O)=O RGXFDHSTXMWMIT-UHFFFAOYSA-N 0.000 description 1
- CUJZSGIHORSMMW-UHFFFAOYSA-N C(C)(=O)O.COC1=C(C=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)CC)O)=O Chemical compound C(C)(=O)O.COC1=C(C=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)CC)O)=O CUJZSGIHORSMMW-UHFFFAOYSA-N 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WHRYRHUTPMKDRR-UHFFFAOYSA-N Cl.C1(=CC=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CN1CCCCC1)O)=O Chemical compound Cl.C1(=CC=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CN1CCCCC1)O)=O WHRYRHUTPMKDRR-UHFFFAOYSA-N 0.000 description 1
- RZFXOMXAUPNHLN-UHFFFAOYSA-N Cl.C1(=CC=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)C)O)=O Chemical compound Cl.C1(=CC=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)C)O)=O RZFXOMXAUPNHLN-UHFFFAOYSA-N 0.000 description 1
- HSPVPJILUFDFTF-UHFFFAOYSA-N Cl.C1(=CC=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)C)O)=O Chemical compound Cl.C1(=CC=CC=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)C)O)=O HSPVPJILUFDFTF-UHFFFAOYSA-N 0.000 description 1
- BJKIENPPZSLSOU-UHFFFAOYSA-N Cl.C1=C(C=CC2=CC=CC=C12)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)C)O)=O Chemical compound Cl.C1=C(C=CC2=CC=CC=C12)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)C)O)=O BJKIENPPZSLSOU-UHFFFAOYSA-N 0.000 description 1
- HCUDUAMZWNCBRK-UHFFFAOYSA-N Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=C(C=C1)OC)OCC(CN1CCCCC1)O)=O Chemical compound Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=C(C=C1)OC)OCC(CN1CCCCC1)O)=O HCUDUAMZWNCBRK-UHFFFAOYSA-N 0.000 description 1
- LWJODJVZNQLVBI-UHFFFAOYSA-N Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)CC)O)=O Chemical compound Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)CC)O)=O LWJODJVZNQLVBI-UHFFFAOYSA-N 0.000 description 1
- VAOHXOASWPOGQT-UHFFFAOYSA-N Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=CC=C1)OCC(CN1CCCCC1)O)=O Chemical compound Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=CC=C1)OCC(CN1CCCCC1)O)=O VAOHXOASWPOGQT-UHFFFAOYSA-N 0.000 description 1
- RWYCJOLKYKBDRU-UHFFFAOYSA-N Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=CC=C1)OCC(CN1CCOCC1)O)=O Chemical compound Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=CC=C1)OCC(CN1CCOCC1)O)=O RWYCJOLKYKBDRU-UHFFFAOYSA-N 0.000 description 1
- CMRDLBZIZSBRPH-UHFFFAOYSA-N Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=CC=C1)OCC(CNCCC)O)=O Chemical compound Cl.CC1=C(C(=CC(=C1)C)C)C(CCC1=CC(=CC=C1)OCC(CNCCC)O)=O CMRDLBZIZSBRPH-UHFFFAOYSA-N 0.000 description 1
- CDQXVPNIMHPLJP-UHFFFAOYSA-N Cl.CC1=CC=C(C=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CN1CCCCC1)O)=O Chemical compound Cl.CC1=CC=C(C=C1)C(CCC1=CC(=C(C=C1)OC)OCC(CN1CCCCC1)O)=O CDQXVPNIMHPLJP-UHFFFAOYSA-N 0.000 description 1
- KACHNOISMHESCD-UHFFFAOYSA-N Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)C)O)=O Chemical compound Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)C)O)=O KACHNOISMHESCD-UHFFFAOYSA-N 0.000 description 1
- QDKLWBIUTOWLBE-UHFFFAOYSA-N Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)CC)O)=O Chemical compound Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)(C)CC)O)=O QDKLWBIUTOWLBE-UHFFFAOYSA-N 0.000 description 1
- OMZGAEQSRNPZTD-UHFFFAOYSA-N Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)C)O)=O Chemical compound Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC(C)C)O)=O OMZGAEQSRNPZTD-UHFFFAOYSA-N 0.000 description 1
- QSORRAOEOXDFDI-UHFFFAOYSA-N Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNCCC)O)=O Chemical compound Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNCCC)O)=O QSORRAOEOXDFDI-UHFFFAOYSA-N 0.000 description 1
- UAVSZMSSFGYAPD-UHFFFAOYSA-N Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=CC=C1)OCC(CNC(C)(C)C)O)=O Chemical compound Cl.COC=1C=C(C=C(C1OC)OC)C(CCC1=CC(=CC=C1)OCC(CNC(C)(C)C)O)=O UAVSZMSSFGYAPD-UHFFFAOYSA-N 0.000 description 1
- JZDJQLAVUUTYEJ-UHFFFAOYSA-N Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC1CCCCC1)O)=O Chemical compound Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNC1CCCCC1)O)=O JZDJQLAVUUTYEJ-UHFFFAOYSA-N 0.000 description 1
- YKWNXBBMJHBWPJ-UHFFFAOYSA-N Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNCCC)O)=O Chemical compound Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=C(C=C1)OC)OCC(CNCCC)O)=O YKWNXBBMJHBWPJ-UHFFFAOYSA-N 0.000 description 1
- QRKOLHQGDZRRDI-UHFFFAOYSA-N Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=CC=C1)OCC(CN1CCOCC1)O)=O Chemical compound Cl.COC=1C=C(C=CC1OC)C(CCC1=CC(=CC=C1)OCC(CN1CCOCC1)O)=O QRKOLHQGDZRRDI-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- VDKMYSMWQCFYBQ-UHFFFAOYSA-N diprafenone Chemical compound CCC(C)(C)NCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 VDKMYSMWQCFYBQ-UHFFFAOYSA-N 0.000 description 1
- 229950002948 diprafenone Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000003742 purkinje fiber Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Die Erfindung betrifft ein Verfahren zur Herstellung von Aminopropanolderivaten von 3-(3-Hydroxyphenyl)-1-propanon-Verbindungen der allgemeinen Formel I, in der die Reste die im Erfindungsanspruch angegebene Bedeutung haben. Diese Verbindungen sind Antiarrhythmika. Formel (I)The invention relates to a process for the preparation of aminopropanol derivatives of 3- (3-hydroxyphenyl) -1-propanone compounds of general formula I in which the radicals have the meaning given in the invention claim. These compounds are antiarrhythmic drugs. Formula (I)
Description
ι· - 4 "ι · - 4 "
Titel der Erfindung:Title of the invention:
Verfahren zur Herstellung von Aminopropanolderi\Aten von 3-(3-Hydroxyphenyl)-1-propanon-Verbindungen und ihrer Säureadditionssalze 20Process for the preparation of aminopropanol derivatives of 3- (3-hydroxyphenyl) -1-propanone compounds and their acid addition salts 20
Die Anwendung der vorliegenden Erfindung erfolgt auf dem Gebiet der Arzneistoffe zur Bekänpfung von Herzarriiythmien, zur Behandlung der koronaren Herzkrankheit und zur Prophylaxe des olötzlichen Herztodes.The application of the present invention is in the field of drugs for the control of cardiac arrhythmias, for the treatment of coronary heart disease and for the prevention of oltzlichen cardiac death.
Charakteristik des bekannten Standes der Technik:Characteristic of the known state of the art:
Aus der DE-PS 20 01 431 ist ein Verfahren zur Herstellung von 2-(2'-Hydroxy-3'-alkylaminopropoxy)-ß-phenylpropiophenone der allgemeinen Formel 35From DE-PS 20 01 431 is a process for the preparation of 2- (2'-hydroxy-3'-alkylaminopropoxy) -ß-phenylpropiophenone of the general formula 35th
sowie deren Säureadditionssalze bekannt. Die n-Propylaminoverbindung (Propafenon) zeigt eine antiarrhythmische Wirksamkeit auf. Aus der Ei--A ü 074 014 ist das 2- [2'-Hydroxy-3'-(1,1-dimethylpropylamino)-propoxy]-ß-phenyl-propiophenon (Diprafenon) und seine Säureadditionssalze bekannt. Ferner sind aus der EP-A 0 075 207 Aminopropano.lderivate der Formeland their acid addition salts known. The n-propylamino compound (propafenone) exhibits antiarrhythmic activity. From the EP-A 0 074 014 is known the 2- [2'-hydroxy-3 '- (1,1-dimethylpropylamino) -propoxy] -β-phenyl-propiophenone (diprafenone) and its acid addition salts. Furthermore, from EP-A 0 075 207 Aminopropano.lderivate the formula
NR1R2 NR 1 R 2
R.R.
4(n)4 (n)
und deren Salze bekannt.and their salts are known.
Typische Beispiele von R-R sind Wasserstoffatome und Alkylreste. η hat einen Wert von 1, 2 oder 3.Typical examples of R-R are hydrogen atoms and alkyl radicals. η has a value of 1, 2 or 3.
Ziel der Erfindung ist es, neue Arzneistoffe zur Bekämpfung von Herzarrhythmien, Behandlung der koronaren Herzkrankheit und zur Prophylaxe des plötzlichen Herztodes zur Verfügung zu stellen.The aim of the invention is to provide new drugs for the treatment of cardiac arrhythmias, treatment of coronary heart disease and for the prevention of sudden cardiac death available.
Der Erfindung liegt die Aufgabe zugrunde, neue Arzneistoffe zur Bekämpfung von Herzarrhythmien zur Behandlung der koronaren Herzkrankheit und zur Prophylaxe des plötzlichen Herztodes zur Verfügung zu stellen.The invention has for its object to provide new drugs for combating cardiac arrhythmias for the treatment of coronary heart disease and for the prevention of sudden cardiac death available.
27 M27 m
·* 5 "·· * 5 "·
Die Erfindung betrifft ein Verfahren zur Herstellung von neuen Aminopropanolderivaten von 3-(3-Hydroxyphenyl)-1-propanon-Verbindungen der allgemeinen Formel IThe invention relates to a process for the preparation of novel aminopropanol derivatives of 3- (3-hydroxyphenyl) -1-propanone compounds of the general formula I.
R3 R 3
0-CH2-CH-CH2-NR R OH0-CH 2 -CH-CH 2 -NR R OH
und ihre Säureadditionssalze.and their acid addition salts.
1 21 2
In der allgemeinen Formel I sind R und R gleich oder verschieden und bedeuten Wasserstoffatome, Alkyl-, Cycloalkyl-, Alkenyl-, Alkinyl- oder Hydroxyalkylreste mit jeweils bis zu 6 C-Atomen, Alkoxyalkyl-, Alkylthioalkyl- oder Dialkylaminoalkylreste mit jeweils bis zu 9 C-Atomen, oder Phenylalkyl- oder Phenoxyalkylreste mit bis zu 6 C-Atomen im Alkylteil, wobei gegebenenfalls der Phenylrest durch einen Alkyl- oder Alkoxyrest mit jeweils bis zu 3 C-Atomen substituiert ist,In the general formula I, R and R are identical or different and denote hydrogen atoms, alkyl, cycloalkyl, alkenyl, alkynyl or hydroxyalkyl radicals having in each case up to 6 C atoms, alkoxyalkyl, alkylthioalkyl or dialkylaminoalkyl radicals having in each case up to 9 C atoms, or phenylalkyl or phenoxyalkyl radicals having up to 6 C atoms in the alkyl moiety, where appropriate the phenyl radical being substituted by an alkyl or alkoxy radical having in each case up to 3 C atoms,
1 21 2
oder R und R bilden zusammen mit dem sie verbindenden Stickstoffatom einen 5- bis 7-gliedrigen gesättigten heterocyclischen Ring, der gegebenenfalls durch einen oder zwei Phenyl- und/oder Hydroxyreste substituiert sein und ein Sauerstoffatom oder Stickstoffatom als weiteres Heteroatom im Ring entiialten kann, wobei das zusätzliche Stickstoffatom durch einen Alkylrest mit 1 bis 3 C-Atomen oder einen Phenylrest substituiert sein kann. R bedeutet ein Wasserstoffatom, einen Alkylrest mit bis zu 3 C-Atomen, ein Fluor-, Chlor- oder Bromatom, eine Kydroxyl- oder Alkoxygruppe mit bis zu 6 C-Atomen. R bedeutet ein Wasserstoff atom, einen Alkylrest mit bis zu 3 C-Atomen, ein Fluor-, Chlor- oder Bromatom, eine Hydroxylgruppe oder eine Alkoxygruppe mit bis zu 6 C-Atomen oder R ist zusammen mit dem daran gebundenen Phenylrest Teil eines anelllerten aromatischen Systems mit bis zu 18 C-Atomen, η ist eine ganze Zahl mit einem Wert von 1 bis 5.or R and R, together with the nitrogen atom connecting them, form a 5- to 7-membered saturated heterocyclic ring which may optionally be substituted by one or two phenyl and / or hydroxy radicals and can form an oxygen atom or nitrogen atom as a further heteroatom in the ring the additional nitrogen atom may be substituted by an alkyl radical having 1 to 3 C atoms or a phenyl radical. R represents a hydrogen atom, an alkyl radical having up to 3 C atoms, a fluorine, chlorine or bromine atom, a hydroxyl or alkoxy group having up to 6 C atoms. R is a hydrogen atom, an alkyl radical having up to 3 C atoms, a fluorine, chlorine or bromine atom, a hydroxyl group or an alkoxy group having up to 6 C atoms or R together with the phenyl radical attached thereto is part of an anelllerten aromatic Systems with up to 18 C atoms, η is an integer from 1 to 5.
Bevorzugt sind Verbindungen, in denen NR R eine tert.-Pentylamino-, n-Propylamino-, 1,1-Dimethylpropylamino-, Morpholine»-, Isopropylamino-, tert.-Butylamino-, Pyrrolidino-,Preference is given to compounds in which NR R is a tert-pentylamino, n-propylamino, 1,1-dimethylpropylamino, morpholine, isopropylamino, tert-butylamino, pyrrolidino,
3 Piperidino- oder Cyclohexylaminogruppe ist, der Rest R ein Wasserstoffatom, eine Methyl-, Methoxy- oder Hydroxylgruppe3 piperidino or cyclohexylamino group, the radical R is a hydrogen atom, a methyl, methoxy or hydroxyl group
4 ist; R sin Wasserstoffatom, eine Methyl-/ Methoxy- oder4 is; R sin hydrogen atom, a methyl / methoxy or
Hydroxylgruppe ist, oder zusammen mit dem daran gebundenen Phenylrest eine 1-Naphthyl-, 2-Naphthyl- oder 3-Phenanthrenylgruppe ist und η den Wert 1, 2 oder 3 hat. 10Is hydroxyl group, or together with the phenyl radical attached thereto is a 1-naphthyl, 2-naphthyl or 3-phenanthrenyl group and η is 1, 2 or 3. 10
1 Besonders bevorzugt sind Verbindungen, in denen NR R" eine1 Particularly preferred are compounds in which NR R "a
tert.-Pentylamino-, n-Propylamino-, Isopropylamino-, tert.-Butylamino-, Piperidino- oder Cyclohexylaminogruppe ist, der Rest R ein Wasserstoffatom, oder eine Methoxygruppe ist, 1^ R4 eine Methyl- oder Methoxygruppe 1st, oder zusammen mit dem daran gebundenen Phenylrest eine 2-Naphthylgruppe ist, und η den Wert 1, 2 oder 3 hat.tert.-pentylamino, n-propylamino, isopropylamino, tert-butylamino, piperidino or cyclohexylamino group, the radical R is a hydrogen atom, or a methoxy group, 1 ^ R 4 is a methyl or methoxy group, or together with the phenyl radical attached thereto is a 2-naphthyl group, and η is 1, 2 or 3.
Am meisten bevorzugt sind 1-(3,4,5-Trimethoxyphenyl)-3-[31-(2-hydroxy-3-tert.-pentylaminopropoxy)-phenyl]-1-propa- non-hydrochlorid (Beispiel 8) .Most preferred are 1- (3,4,5-trimethoxyphenyl) -3- [3 1 - (2-hydroxy-3-tert-pentylaminopropoxy) phenyl] -1-propanone hydrochloride (Example 8).
1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-tert.-butylaminopropoxy)-phenyl]-1-propanon-hydrochlorid (Beispiel 17).1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-tert-butylaminopropoxy) -phenyl] -1-propanone hydrochloride (Example 17).
1-(3,4-Dimethoxyphenyl)-3-[3'-(2-hydroxy-3-isopropylaminopropoxy)-4·-methoxyphenyl]-1-propanon-hydrochlorid (Beispiel 23).1- (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-isopropylaminopropoxy) -4-methoxyphenyl] -1-propanone hydrochloride (Example 23).
1-(3,4,5-Trimethoxyphenyl)-3-[3·-(Z-hydroxy-S-cyclohexylaminopropoxy) -4' -methoxyphenyj,] Ί -propanon-hydrochlorid (Beispiel 32)1- (3,4,5-trimethoxyphenyl) -3- [3 · - (Z-hydroxy-S-cyclohexylaminopropoxy) -4'-methoxyphenyl], -] -propanone hydrochloride (Example 32)
ι_(2-Naphthyl)-3-[3'-(2-hydroxy-3-n-propylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid (Beispiel 48). ι_ (2-Naphthyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride (Example 48).
Das erfindungsgemäße Verfahren zur Herstellung der Verbindungen der allgemeinen Formel I und ihrer Säureadditionssalze ist dadurch gekennzeichnet, daß man einen Phenoläther der allgemeinen Formel IIThe process according to the invention for the preparation of the compounds of the general formula I and their acid addition salts is characterized in that a phenol ether of the general formula II
CH^-CH„-CQ-// \CH ^ -CH "-CQ - // \
O mit einem Amin der allgemeinen Formel IIIO with an amine of the general formula III
HNR1R2 (III)HNR 1 R 2 (III)
umsetzt.implements.
R , R*, R , R und η haben die vorstehend angegebene Bedeutung.R, R *, R, R and η are as defined above.
Gegebenenfalls wird die erhaltene Verbindung der allgemeinen Formel I mit einer Säure in ein Säureadditionssalz überführt. Tie Umsetzung kann beispielsweise nach dem in der EP-PS 0 074 014 beschriebenen Verfahren erfolgen.Optionally, the resulting compound of general formula I is converted with an acid into an acid addition salt. Tie implementation can be done for example by the method described in EP-PS 0 074 014.
*® Die Umsetzung wird bei Temperaturen von 10 bis 1200C, d.h. * ® The reaction is carried out at temperatures of 10 to 120 0 C, ie
bei Raumtemperatur oder bei höheren Temperaturen, zweckmäßig bei Temperaturen von 50 bis 120°C unter Atmosphärendruck oder in einem geschlossenen Gefäß unter erhöhtem Druck durchgeführt .at room temperature or at higher temperatures, suitably carried out at temperatures of 50 to 120 ° C under atmospheric pressure or in a closed vessel under elevated pressure.
Die Ausgangsverbindungen der allgemeinen Formel II und III können ohne Verdünnungs- oder Lösungsmittel umgesetzt werden. Zweckmäßigerweise werden die Umsetzungen jedoch durchgeführt in Gegenwart eines inerten Verdünnungs- oder Lösungsmittels,The starting compounds of general formula II and III can be reacted without diluent or solvent. Conveniently, however, the reactions are carried out in the presence of an inert diluent or solvent,
beispielsweise eines niederen Alkohols mit i bis 4 C-Atomen, wie Methanol, Äthanol oder Propanol, vorzugsweise Isopropanol oder Äthanol, eines niederen gesättigten Dialkyläthers, Dialkylglykoläthers oder cyclischen Äthers, wie Diäthyläther, 1,2-Dimethoxyäthan, Tetrahydrofuran oder Dioxan, eines Benzolkohlenwasserstoffs, wie Benzol selbst oder eines.Alkylbenzols, insbesondere Toluol oder Xylol, oder eines aliphati-for example, a lower alcohol having 1 to 4 carbon atoms, such as methanol, ethanol or propanol, preferably isopropanol or ethanol, a lower saturated dialkyl ether, Dialkylglykoläthers or cyclic ether, such as diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran or dioxane, a benzene hydrocarbon, such as benzene itself or an alkylbenzene, in particular toluene or xylene, or an aliphatic
2 7 I ί Ο2 7 I ί Ο
Kohlenwasserstoffs, wie Hexan, Heptan oder Octan, Dimethylsulfoxid oder in Gegenwart von Wasser oder Mischungen der genannten Lösungsmittel.Hydrocarbon, such as hexane, heptane or octane, dimethyl sulfoxide or in the presence of water or mixtures of said solvents.
Auch ist das in überschüssiger Menge verwendete Amin der allgemeinen Formel III gegebenenfalls als Verdünnungs- oder Lösungsmittel geeignet.Also, the amine of general formula III used in excess amount is optionally suitable as a diluent or solvent.
Die vollständige Umsetzung hängt von der Reaktionstemperatur ab und ist im allgemeinen innerhalb von 2 bis 15 Stunden beendet. Das Reaktionsprodukt kann in an sich üblicher Weise gewonnen werden, z.B. durch Filtration oder Abdestillieren. des Verdünnungsmittels aus dem Reaktionsgemisch. Eine Reinigung der erhaltenen Verbindung erfolgt in üblicher Weise, beispielsweise durch Umkristallisation aus einem Lösungsmittel, überführen in ein Säureadditionssalz oder durch Säulenchromatographie.·The complete reaction depends on the reaction temperature and is generally completed within 2 to 15 hours. The reaction product can be recovered in a conventional manner, e.g. by filtration or distilling off. of the diluent from the reaction mixture. The compound obtained is purified in a customary manner, for example by recrystallization from a solvent, conversion into an acid addition salt or by column chromatography.
Der Phenoläther der allgemeinen Formel II kann durch Alkylierung eines 3-Hydroxy-ß-phenylpropio^phenons der allgemeinen Formel IVThe phenol ether of the general formula II can be obtained by alkylation of a 3-hydroxy-.beta.-phenylpropiophene phenone of the general formula IV
.4.4
3 4 mit einem Epj^Jialogenhydrin erhalten werden. R , R und η haben die vorstehend angegebene Bedeutung. Als Epihalogenhydrine kommen Epichlorhydrin, Epibromhydrin und Epijodhydrin in Betracht.3 4 can be obtained with a Epj ^ Jialogenhydrin. R, R and η are as defined above. Suitable epihalohydrins are epichlorohydrin, epibromohydrin and epiiodohydrin.
Die Umsetzung der .Verbindungen IV zur Herstellung der Ausgangsverbindungen der allgemeinen Formel II wird zweckmäßig bei Temperaturen von 0 bis 1200C und unter Normaldruck oder in einem geschlossenen Gefäß unter erhöhtem Druck durchge-The reaction of the .Compounds IV for preparing the starting compounds of general formula II is conveniently carried out at temperatures from 0 to 120 0 C and under atmospheric pressure or in a closed vessel under elevated pressure carried
führt. Als Lösungs- oder Verdünnungsmittel werden zweckmäßig ein niederes aliphatisches Keton, wie Aceton, Methyläthylketon oder Methylisobutylketon, ein niederer Alkohol mit 1 bis 4 C-Atomen, wie Methanol, Äthanol, Propanol oder Butanol, ein niederer aliphatischer oder cyclischer Äther, wie Diäthyläther, Tetrahydrofuran oder Dioxan, ein DiaJkylformamid, wie Dimethylformamid oder Diäthy1formamid, oder Dimethylsulfoxid oder Hexamethylphosphorsäuretriamid oder überschüssiges Alkylierungsmittel verwendet.leads. Suitable solvents or diluents are suitably a lower aliphatic ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, a lower alcohol having 1 to 4 carbon atoms, such as methanol, ethanol, propanol or butanol, a lower aliphatic or cyclic ether, such as diethyl ether, tetrahydrofuran or dioxane, a di-alkylformamide such as dimethylformamide or diethylformamide, or dimethylsulfoxide or hexamethylphosphoric triamide or excess alkylating agent.
Bevorzugt werden die Umsetzungen in Gegenwart einer Base als säurehindendes Mittel durchgeführt. Geeignete Basen sind · Alkalimetallcarbonate, -hydrogencarbonate, -hydroxide, -hydride oder -alkoholate, insbesondere von Natrium und Kalium, basische Oxide, wie Aluminiumoxid oder Calciumoxid, organische tertiäre Basen, wie Pyridin, niedere Trialkylamine, wie -Trimethyl- oder Triäthylamin, oder Piperidin. Dabei können die Basen im Verhältnis zum eingesetzten Alkylierungsmittel in katalytischer Menge oder in stöchiometrischer Menge bzw. in geringem Überschuß verwendet werden.Preferably, the reactions are carried out in the presence of a base as the acid-retaining agent. Suitable bases are: alkali metal carbonates, bicarbonates, hydroxides, hydrides or alcoholates, in particular of sodium and potassium, basic oxides, such as aluminum oxide or calcium oxide, organic tertiary bases, such as pyridine, lower trialkylamines, such as trimethylamine or triethylamine, or piperidine. The bases can be used in relation to the alkylating agent used in catalytic amount or in stoichiometric amount or in slight excess.
Bevorzugt wird das S-Hydroxy-ß-phenylpropio^henon mit Epichlorhydrin oder Epibromhydrin in einem polaren, aprotischen Lösungsmittel, insbesondere Dimethylsulfoxid, in Gegenwart von mindestens einem Moläquivalent Base, insbesondere Natriumhydrid, bezogen auf das Alkylierungsmittel, bei Temperaturen von 0 bis 500C umgesetzt.Preferably, the S-hydroxy-ß-phenylpropio ^ henone with epichlorohydrin or epibromohydrin in a polar, aprotic solvent, in particular dimethyl sulfoxide, in the presence of at least one molar equivalent of base, in particular sodium hydride, based on the alkylating agent, at temperatures from 0 to 50 0 C. implemented.
Die Ausgangsverbindung der allgemeinen Formel IV, d.h. das 3-Hydroxy-ß-phenylpropiophenon, und seine Herstellung 1st bekannt.The starting compound of general formula IV, i. 3-hydroxy-.beta.-phenylpropiophenone, and its preparation is known.
• Gegebenenfalls wird die erhaltene erfindungsgemäß hergestellte Verbindung der Formel I in ein Säureadditionssalz, vorzugsweise in ein Salz einer physiologisch verträglichen Säure überführt, übliche physiologisch verträgliche anorganische undOptionally, the resulting compound of the formula I prepared according to the invention is converted into an acid addition salt, preferably into a salt of a physiologically acceptable acid, customary physiologically compatible inorganic and
organische Säuren sind beispielsweise Salzsäure, Bromwasserstoff säure, Phosphorsäure, Schwefelsäure, Oxalsäure, Maleinsäure, Fumarsäure, Milchsäure, Weinsäure, Äpfelsäure, Citronensäure, Salicylsäure, Adipinsäure und Benzoesäure. Weitere verwendbare Säuren sind beschrieben z.B. in Fortschritte der Arzneimittelf or schung, Bd. 10, Seiten 224 - 225, Birkhäuser Verlag, Basel und Stuttgart, 1966, und Journal of Pharmaceutical Sciences Bd. 66, Seiten 1-5 (1977). Bevorzugt ist Salzsäure.Organic acids are, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid. Other acids which can be used are described e.g. in Advances in Drug Science, Vol. 10, pp. 224-225, Birkhäuser Verlag, Basel and Stuttgart, 1966, and Journal of Pharmaceutical Sciences Vol. 66, pp. 1-5 (1977). Preference is given to hydrochloric acid.
Die Säureadditionssalze werden in der Regel in an sich bekannter Weise durch Mischen der freien Base oder deren Lösungen mit der entsprechenden Säure oder deren Lösungen in einem organischen Lösungsmittel, beispielsweise einem niederen Alkohol, wie Methanol, Äthanol, n-Propanol oder Isopropanol, oder einem niederen Keton, wie Aceton, Methyläthylketon oder Methyl-isobutylketon, oder einem Äther, wie Diäthyläther, Tetrahydrofuran oder Dioxan, erhalten. Zur besseren Kristallabscheidung können auch Mischungen der genannten Lösungsmittel verwendet werden. Darüber hinaus können pharmazeutisch verträgliche wäßrige Lösungen von Säureadditionsalzen der Verbindung der Formel I in einer wäßrigen Säurelösung hergestellt werden. 'The acid addition salts are usually in a conventional manner by mixing the free base or its solutions with the corresponding acid or its solutions in an organic solvent, for example a lower alcohol such as methanol, ethanol, n-propanol or isopropanol, or a lower Ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, or an ether, such as diethyl ether, tetrahydrofuran or dioxane. For better crystal separation, it is also possible to use mixtures of the abovementioned solvents. In addition, pharmaceutically acceptable aqueous solutions of acid addition salts of the compound of formula I can be prepared in an aqueous acid solution. '
Die Säureadditionssalze der Verbindung der Formel I können in an sich bekannter Weise, z.B. mit Alkalien oder Ionenaustauschern, in die freie Base übergeführt werden. Von der freien Base lassen sich durch Umsetzung mit anorganischen oder organischen Säuren, insbesondere solchen, die zur Bildung von therapeutisch verwendbaren Salzen geeignet sind, weitere Salze gewinnen. Diese oder auci. andere Salze der neuen Verbindung, wie z.B. das Pikrat, können auch zur Reinigung der freien Base dienen, indem man die freie Base in ein Salz überführt, dieses abtrennt und aus dem Salz wiederum die Base'freisetzt.The acid addition salts of the compound of the formula I can be prepared in a manner known per se, e.g. with alkalis or ion exchangers are converted into the free base. From the free base, further salts can be obtained by reaction with inorganic or organic acids, in particular those which are suitable for the formation of therapeutically usable salts. This or auci. other salts of the new compound, e.g. The picrate may also serve to purify the free base by salting the free base, separating it, and releasing the base again from the salt.
27 \ i O27 \ i o
Die erfindungsgemäß hergestellte Verbindung kann oral, rektal, intravenös oder intramuskulär appliziert werden.The compound prepared according to the invention can be administered orally, rectally, intravenously or intramuscularly.
Die erfindungsgemäß hergestellten Verbindungen und ihre physiologisch verträglichen Säureadditionssalze sind insbesondere wegen ihrer antiarrhythmischen und ß-sympatholytischen Eigenschaften, vor allem zur Pharmakotherapie von Herzrhythmusstörungen, zur Behandlung der koronaren Herzkrankheit und zur Prophylaxe des plötzlichen Herztodes geeignet. Die antiarrhythmische Wirksamkeit der erfindungsgemäß hergestellten Verbindungen wurde sowohl anhand von elektrophysiologischen Studien an Purkinje-Fasern aus Hundeherzen sowie mit Hilfe von Ouabain-induzierten ventrikulären Tachykardien bei Hunden bestimmt.The compounds according to the invention and their physiologically acceptable acid addition salts are particularly suitable because of their antiarrhythmic and ß-sympatholytic properties, especially for the pharmacotherapy of cardiac arrhythmias, for the treatment of coronary heart disease and for the prevention of sudden cardiac death. The antiarrhythmic activity of the compounds according to the invention was determined both on the basis of electrophysiological studies on Purkinje fibers from dog hearts and with the aid of ouabain-induced ventricular tachycardias in dogs.
Die erfindungsgemäß hergestellten Verbindungen werden in den nachstehenden Tabellen I und II mit Propafenon (A) verglichen.The compounds prepared according to the invention are compared in the following Tables I and II with propafenone (A).
Die Wirkung auf die Kontraktionskraft des Herzens wurde am Meerschweinchen-Papillarmuskel untersucht. Hämodynamische Studien wurden bei gesunden, wie auch akut infarzierten Hun- . den durchgeführt. In der folgenden Tabelle I wird als wichtiges Kriterium der Sicherheitsfaktor (S.F.) dargestellt, der , 25 sich aus dem Verhältnis der antiarrhythmischen Wirksamkeit (Leitungsverzögerung C20 Vmax) zur negativen Inotropie (C20 CF) und eier spezifisch stärkeren Wirksamkeit bei höheren Frequenzen (Rate-Faktor von Vmax) ergibt. Vergleichend sei hierbei erwähnt, daß die zur Zeit führenden Antiarrhythmika Propafenon und Flecainid ein S.F. von 1,5 bzw. 1,7 haben.The effect on the contraction force of the heart was examined on guinea pig papillary muscle. Haemodynamic studies have been conducted in healthy as well as acutely infarcted dogs. the performed. In the following Table I is presented as an important criterion the safety factor (SF) , 25, the ratio of the antiarrhythmic efficacy (conduction delay C20 Vmax) to negative inotropy (C20 CF) and eggs specifically stronger efficacy at higher frequencies (rate factor from Vmax). By way of comparison, it should be mentioned that the currently leading antiarrhythmics propafenone and flecainide have an SF of 1.5 and 1.7, respectively.
Als zusätzliches Kriterium wurde der Vorzeitigkeitsindex (Prematurity-Faktor) bestimmt, der die erwünschte Wirksamkeit der erfindungsgemäß hergestellten Verbindungen bei frühzeitig C5 einfallenden Extrasystolen charakterisiert.As an additional criterion, the prematurity index (prematurity factor) was determined, which characterizes the desired activity of the compounds according to the invention in premature C5 extrinsic islets.
Die hohe antiarrhythmische Wirksamkeit ist nicht begleitet von einer signifikanten Toxizitätssteigerung im Vergleich zu Propafenon. Dies ergibt sich aus einem Vergleich der LD50-Werte bei Ratten und Mäusen, die in Tabelle II zusammengefaßt sind.The high antiarrhythmic efficacy is not accompanied by a significant increase in toxicity compared to propafenone. This results from a comparison of the LD 50 values in rats and mice, which are summarized in Table II.
- 14 Tabelle I- 14 Table I
um 20 % verringert C20 Vmax: Konzentration, die Vmax bei einer Zykluslange von-1000 mSek.decreased by 20 % C20 Vmax: Concentration, the Vmax at a cycle length of -1000 msec.
um 20 % verringertreduced by 20 %
2 7 H O2 7 H O
Rate-Faktor von Vmax:Rate factor of Vmax:
Prematurity Faktor Vmax:Prematurity Factor Vmax:
- 15-- 15-
(% des Kontrollwertes Vmax bei einer Zyklus länge von 2000) / (% des Kontrollwertes Vmax bei einer Zykluslänge von 500) bei C20 Vmax {% des Kontrollwertes Vmax bei vorzeitigen Extrasystolen ) (% des Kontrollwertes Vmax bei einem Normalschlag) bei Vmax (% of control value Vmax for a cycle length of 2000) / (% of control value Vmax for a cycle length of 500) for C20 Vmax {% of control value Vmax for premature extrasystoles) (% of control value Vmax for a normal beat) for Vmax
S.F.:S.F .:
Sicherheitsfaktor, errechnet als Rate-Faktor von Vmax * (C20 CF /C20 Vmax)Safety factor, calculated as rate factor of Vmax * (C20 CF / C20 Vmax)
2Q Ausführungsbeispiele: 2Q embodiments:
A) Herstellung der AusgangsverbindungenA) Preparation of the starting compounds
1-(3,4-Dimethoxyphenyl)-3-[3'-(1,2-epoxy-3-propoxy)-phenyl]-1-propanon1- (3,4-dimethoxyphenyl) -3- [3 '- (1,2-epoxy-3-propoxy) -phenyl] -1-propanone
100 g (0,35 Mol) 3,4-Dimethoxy-ß-3'-hydroxyphenyl-propiophenon werden mit 300 ml Epichlorhydrin und 24,2 g (0,175 Mol) Kaliumcarbonat 23 h unter Rückfluß erhitzt und gerührt. Das entstandene Salz wird abfiltriert und die verbleibende Lösung unter vermindertem Druck zur Trockene eingeengt. Der Rückstand wird aus Isoprop?.nol umkristallisiert. Ausbeute 109,8 g (91,9 %) der Titelverbindung vom Fp. 81 - 84°C.100 g (0.35 mol) of 3,4-dimethoxy-β-3'-hydroxyphenyl-propiophenone are refluxed with 300 ml of epichlorohydrin and 24.2 g (0.175 mol) of potassium carbonate for 23 h and stirred. The resulting salt is filtered off and the remaining solution is concentrated to dryness under reduced pressure. The residue is recrystallized from isopropanol. Yield: 109.8 g (91.9%) of the title compound, m.p. 81-84 ° C.
-16-Analog wurden folgende Verbindungen hergestellt:16 analogue, the following compounds were prepared:
1-(4-Methoxypheny1)-3-[3·-(1,2-epoxy-3-propoxy)-phenyl] -1 -1- (4-methoxyphenyl) -3- [3 · - (1,2-epoxy-3-propoxy) -phenyl] -1 -
propanon 1-(3,4,5-Trimethoxyphenyl)-3-[3'-(1,2-epoxy-3-propoxy)-Propanone 1- (3,4,5-trimethoxyphenyl) -3- [3 '- (1,2-epoxy-3-propoxy) -
phenyl]-1-propanon 1-(2,4,6-Trimethylphenyl)-3-[3·-(1,2-epoxy-3-propoxy)-phenyl]-1-propanonphenyl] -1-propanone 1- (2,4,6-trimethylphenyl) -3- [3 · - (1,2-epoxy-3-propoxy) -phenyl] -1-propanone
1-Phenyl-3-[3'-(1,2-epoxy-3-propoxy)-4'-methoxy-phenyl]-1-propanon1-Phenyl-3- [3 '- (1,2-epoxy-3-propoxy) -4'-methoxy-phenyl] -1-propanone
1-(3,4-Dimethoxyphenyl)-3-[3'—(1,2-epoxy-3-propoxy)-4'-meth-1- (3,4-dimethoxyphenyl) -3- [3 '- (1,2-epoxy-3-propoxy) -4'-meth-
oxypheny1]-1-propanon 1-(3,4,5-Trimethoxyphenyl)—3—[3·-(ί,2-epoxy-3-propoxy)-4'-methoxy-phenyl]-1-propanonoxypheny1] -1-propanone 1- (3,4,5-trimethoxyphenyl) -3- [3 · - (ί, 2-epoxy-3-propoxy) -4'-methoxyphenyl] -1-propanone
-j- (2-Methoxyphenyl) —3— [3· — (1,2-epoxy-3-propoxy) -4' -methoxyphenyl ]-1-propanon-j- (2-methoxyphenyl) -3- [3 · - (1,2-epoxy-3-propoxy) -4'-methoxyphenyl] -1-propanone
1-(4-Methylphenyl)-3-[3'-(1,2-epoxy-3-propoxy)-4'-methoxyphenyl] -1-propanon1- (4-methylphenyl) -3- [3 '- (1,2-epoxy-3-propoxy) -4'-methoxyphenyl] -1-propanone
1-(2,4,6-Trimethylphenyl)-3-[3'-(1,2-epoxy-3-propoxy)-4'-methoxy-pheny1]-1-propanon1- (2,4,6-trimethylphenyl) -3- [3 '- (1,2-epoxy-3-propoxy) -4'-methoxy-pheny1] -1-propanone
1-(2-Naphthyl)—3—[3'—(1,2-epoxy-3-propoxy)-4'-methoxyphenyl]-1-propanon1- (2-naphthyl) -3- [3 '- (1,2-epoxy-3-propoxy) -4-methoxyphenyl] -1-propanone
13,1 g (0,04 Mol) 1-(2-Naphthyl)-3-(3'-hydroxy-4·-methoxyphenyl) -1-propanon werden mit 26,3 ml Epichlorhydrin, 90 ml Isopropanol und 1,6 g (0,04 Mol) Natriumhydroxid 5 h unter Rückfluß erhitzt. Das entstandene Salz wird abtiltriert und die verbleibende Lösung unter vermindertem Druck eingeengt. Der verbleibende ölige Rückstand wird ohne Reinigung in die nächste Stufe eingesetzt. Ausbeute: 16,4 g ("31M00%).13.1 g (0.04 mol) of 1- (2-naphthyl) -3- (3'-hydroxy-4-methoxyphenyl) -1-propanone are mixed with 26.3 ml of epichlorohydrin, 90 ml of isopropanol and 1.6 g (0.04 mol) of sodium hydroxide for 5 h under reflux. The resulting salt is filtered off and the remaining solution is concentrated under reduced pressure. The remaining oily residue is used without purification in the next stage. Yield: 16.4 g (" 31 M00%).
- 17 Beispiel III - 17 Example III
1-(3-Phenanthrenyl)-3-[3'-(1,2-epoxy-3-propoxy)-phenyl]-1-propanon 51- (3-phenanthrenyl) -3- [3 '- (1,2-epoxy-3-propoxy) -phenyl] -1-propanone 5
61,6 g (0,18 Mol) 1-(3-Phenantrhenyl)-3-(3'-hydroxyphenyl)-1-propanon werden mit 105,6 ml Epichlorhydrin, 66 ml Methanol und 7,2 g (0,18 Mol) Natriumhydroxid 12 h unter Rückfluß erhitzt. Jas entstandene Salz wird abfiltriert und die verbleibende Lösung unter vermindertem Druck eingeengt. Der Rückstand wird ohne Reinigung in die nächste Stufe eingesetzt. Ausbeute: 65,2 g(?85,3 %) .61.6 g (0.18 mol) of 1- (3-phenantrhenyl) -3- (3'-hydroxyphenyl) -1-propanone are mixed with 105.6 ml of epichlorohydrin, 66 ml of methanol and 7.2 g (0.18 Mol) sodium hydroxide for 12 h under reflux. Jas salt formed is filtered off and the remaining solution concentrated under reduced pressure. The residue is used without purification in the next stage. Yield: 65.2 g (? 85.3%).
B) Herstellung der Verbindungen der allgemeinen Formel (I) 15B) Preparation of the compounds of general formula (I) 15
1-(3,4-Dimethoxyphenyl)-3-[3·-(2-hydroxy-3-tert.-pentylaminopropoxy)-phenyl]-1-propanon-hydrochlorid1- (3,4-dimethoxyphenyl) -3- [3 · - (2-hydroxy-3-tert-pentylaminopropoxy) -phenyl] -1-propanone hydrochloride
27,4 g (0,08 Mol) 1-(3,4-Dimethoxyphenyl)-3-[3'-(1,2-epoxy-3-propoxy)-phenyl]-1-propanon und 20,9 g (0,24 Mol) tert.-Pentylamin werden in 300 ml Methanol gelöst und 4 h unter Rückfluß erhitzt. Das Lösungsmittel und das überschüssige Amin werden unter vermindertem Druck entfernt. Der ölige Rückstand wird in Methanol aufgenommen und mit konzentrierter Salzsäure versetzt. Nach dem Erhitzen und Abkühlen werden Kristalle erhalten, die aus Aceton umkristallisiert werden. Ausbeute: 22,8 g (61,2 %) der Titelverbindung vom Fp. 117 -27.4 g (0.08 mol) of 1- (3,4-dimethoxyphenyl) -3- [3 '- (1,2-epoxy-3-propoxy) -phenyl] -1-propanone and 20.9 g ( 0.24 mol) of tert-pentylamine are dissolved in 300 ml of methanol and heated under reflux for 4 h. The solvent and the excess amine are removed under reduced pressure. The oily residue is taken up in methanol and treated with concentrated hydrochloric acid. After heating and cooling, crystals are obtained which are recrystallized from acetone. Yield: 22.8 g (61.2%) of the title compound of mp 117-
119°C.119 ° C.
Analog wurden hergestellt (Beispiele 2 bis 51):Analog were prepared (Examples 2 to 51):
2. 1-(3,4-Dimethoxyphenyl)-3-[3·-(2-hydroxy-3-n-propylaminopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 146 147°C.2. 1- (3,4-Dimethoxyphenyl) -3- [3 · - (2-hydroxy-3-n-propylaminopropoxy) phenyl] -1-propanone hydrochloride, m.p .: 146 147 ° C.
2 7 ί ί Ο2 7 ί ί Ο
• - 18 -• - 18 -
3. 1- (3,4-Dimethoxyphenyl) -3- [3 ' - (2-hydroxy-3->morpholinopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 148 - 149°C3. 1- (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-morpholinopropoxy) phenyl] -1-propanone hydrochloride, m.p .: 148-149 ° C
4. 1-(3,4-Dimethoxyphenyl)-3-[3'-(2-hydroxy-3-isopropylamino-propoxy)-phenyl]-1-propanon-hydrochlorid, . Fp.: 175-177°C.4. 1- (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-isopropylamino-propoxy) -phenyl] -1-propanone hydrochloride,. Mp .: 175-177 ° C.
5. 1 - (3,4-Dimethoxyphenyl-3-[3 -(2-hydroxy-3-tert.-butylamino-propoxy)-phenyl]-1-propanon-hydrochlorid/ Fp.: 179 - 181°C.5. 1- (3,4-Dimethoxyphenyl-3- [3- (2-hydroxy-3-tert-butylamino-propoxy) -phenyl] -1-propanone hydrochloride / m.p .: 179-181 ° C.
6. 1-(3,4-Dimethoxyphenyl)-3-[3'-(2-hydroxy-3-piperidinopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 141-142°C.6. 1- (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-piperidinopropoxy) -phenyl] -1-propanone hydrochloride, m.p .: 141-142 ° C.
7. 1-(4-Methoxyphenyl)-3-[3'-(2-hydroxy-3-n-propylaminoprop-•oxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 128,5-129,50C;7. 1- (4-Methoxyphenyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) -1-propanone hydrochloride, m.p .: 128.5-129.5 0 C;
8. 1-(3,4,5-Trimethoxypheny1)-3-[3·-(2-hydroxy-3-tert.-pentylaminopropoxy)-phenyl]-1-propanon-hydrochlorid,8. 1- (3,4,5-trimethoxyphenyl) -3- [3 · - (2-hydroxy-3-tert-pentylaminopropoxy) -phenyl] -1-propanone hydrochloride,
Fp.: 160-1610C. .Mp .: 160-161 0C.
9. 1-(3,4,5-Trimethoxyphenyl)-3-[31-(2-hydroxy-3-isopropylamino-propoxy)-phenyl]-1-propanon-hydrochlorid,9. 1- (3,4,5-trimethoxyphenyl) -3- [3 1 - (2-hydroxy-3-isopropylamino-propoxy) -phenyl] -1-propanone hydrochloride,
Fp.: 119,5-120,50CMp .: 119.5 to 120.5 0 C
25 25
10. 1-(3,4,5-Trimethoxypheny1)-3-[3'-(2-hydroxy-3-tert.-butylaminopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 158-159°C.10. 1- (3,4,5-Trimethoxyphenyl) -3- [3 '- (2-hydroxy-3-tert-butylaminopropoxy) phenyl] -1-propanone hydrochloride, m.p .: 158-159 ° C ,
11. 1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-2-tert.-pentyl-aminopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 103-1050C.11. 1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-2-tert-pentyl-aminopropoxy) -phenyl] -1-propanone hydrochloride, mp 103-105 0 C.
12. 1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-piperidinopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 158-159,5°C.12. 1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-piperidinopropoxy) -phenyl] -1-propanone hydrochloride, m.p .: 158-159.5 ° C.
13. 1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-morpholinopropoxy)-phenylJ-i-propanon-hydrochlorid, Fp.: 170 - 171°C.13. 1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-morpholinopropoxy) -phenyl] -i-propanone hydrochloride, m.p .: 170-171 ° C.
14. 1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-tert.-butyl-aminopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 129 - 131°C.14. 1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-tert-butyl-aminopropoxy) -phenyl] -1-propanone hydrochloride, m.p .: 129-131 ° C.
15. 1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-isopropylaminopropoxy)-phenyl]-1-propanon-semioxalat, Fp.: 146 - 148°C.15. 1- (2,4,6-Trimethylphenyl) -3- [3 '- (2-hydroxy-3-isopropylaminopropoxy) phenyl] -1-propanone semioxalate, m.p .: 146-148 ° C.
16. 1 - (2,4,6-Trimethylphenyl) -3- [3 '~(2-hydroxy-3-n-propylaminopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 84-85°C.16. 1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) -phenyl] -1-propanone hydrochloride, m.p .: 84-85 ° C.
17. 1 - (2, 4", 6-Trimethylphenyl) -3- [3 ' - (2-hydroxy-3-tert. -butylaminopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 123,5-125,5°C.17. 1 - (2,4 ', 6-Trimethylphenyl) -3- [3' - (2-hydroxy-3-tert-butylaminopropoxy) phenyl] -1-propanone hydrochloride, m.p .: 123.5% 125.5 ° C.
jj
18. 1-Phenyl-3- [3'-(2-hydroxy-3-tert.-pentylaminopropoxy)-4'-methoxyphenyl]-1-propanon-semi-oxalat, Fp.: 162-164°C.18. 1-Phenyl-3- [3 '- (2-hydroxy-3-tert-pentylaminopropoxy) -4'-methoxyphenyl] -1-propanone semi-oxalate, m.p .: 162-164 ° C.
19. 1-Phenyl-3-[3'-(2-hydroxy-3-isopropylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 157~158°C.19. 1-Phenyl-3- [3 '- (2-hydroxy-3-isopropylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p. 157-158 ° C.
20. 1-Phenyl-3-[3'-(2-hydroxy-3-tert.-butylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 158-159°C.20. 1-Phenyl-3- [3 '- (2-hydroxy-3-tert-butylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 158-159 ° C.
21. 1-Phenyl-3-[3'-(2-hydroxy-3-piperidinopropoxy)-4'-methoxyphenyl] -1-propanon-hydrochlorid, Fp.: 115-117°C,21. 1-Phenyl-3- [3 '- (2-hydroxy-3-piperidinopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 115-117 ° C,
22. 1-(3,4-Dimethoxyphenyl)-3-[3'-(2-hydroxy-3-n-propylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 115-116,5°C.22. 1- (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p. 115-116.5 ° C.
-20 - .-20 -.
23. 1-(3,4-Dimethoxypheny1)-3-[3'-(2-hydroxy-3-isopropylaminopropoxy)-4·-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 128-131°C.23. 1- (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-isopropylaminopropoxy) -4 -methoxyphenyl] -1-propanone hydrochloride, m.p .: 128-131 ° C.
24. 1-(3,4-Dimethoxyphenyl)-3-[3'-(2-hydroxy-3-morpholinopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 158-161°C.24. 1- (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-morpholinopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 158-161 ° C.
25. 1-(3,4-Dimethoxyphenyl)-3-[3'-(2-hydroxy-3-tert.-butylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 168-1700C.25. 1- (3,4-dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-tert.-butylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 168-170 0 C.
26. 1 -(3,4-Dimethoxypheny1)-3-[3'-(2-hydroxy-3-cyclohexylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 117,5-120,50C.26. 1 - (3,4-Dimethoxyphenyl) -3- [3 '- (2-hydroxy-3-cyclohexylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 117.5-120.5 0 C.
. 27. 1-(3,4-Dimethoxypheny1)-3-[31-(2-hydroxy-3-tert.-pentylaminopropoxy) -4·-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 147-148°C, 27. 1- (3,4-Dimethoxyphenyl) -3- [3 1 - (2-hydroxy-3-tert-pentylaminopropoxy) -4-methoxyphenyl] -1-propanone hydrochloride, m.p .: 147-148 ° C
20 20
28. 1-(3,4,5-Trimethoxyphenyl)-3- [3'-(2-hydroxy-3-tert.-pentylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 126-129°C.28. 1- (3,4,5-Trimethoxyphenyl) -3- [3 '- (2-hydroxy-3-tert-pentylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p. 129 ° C.
29. 1-(3,4,5-Trimethoxyphenyl)-3-[3'-(2-hydroxy-3-n-propylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 103,5-1060C.29. 1- (3,4,5-Trimethoxyphenyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 103.5 -106 0 C.
30. 1-(3,4,5-Trimethoxyphenyl)-3-[3'-(2-hydroxy-3-isopropylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 115-116°C.30. 1- (3,4,5-Trimethoxyphenyl) -3- [3 '- (2-hydroxy-3-isopropylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 115-116 ° C ,
31. 1-(3,4,5-Trimethoxyphenyl)-3-[3'-(2-hydroxy-3-tert.-butylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydro- chlorid, Fp.: 150,5-1520C.31. 1- (3,4,5-Trimethoxyphenyl) -3- [3 '- (2-hydroxy-3-tert-butylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 150.5-152 0 C.
27 η O27 η O
- 21 - - 21 -
32. 1 - (3·, 4 , 5-Trimethoxyphenyl) -3- [3 ' - (2-hydroxy-3-cyclohexylamihopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 136,5-138,50C.32. 1 - (3 ·, 4, 5-Trimethoxyphenyl) -3- [3 '- (2-hydroxy-3-cyclohexylamihopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 136.5- 138.5 0 C.
33. 1-(2-Methoxyphenyl)-3-[3'-(2-hydroxy-3-tert.-pentylaminopropoxy)-4'-methoxyphenyl]-1-propanon-acetat, Fp.: 119-1200C.33. 1- (2-Methoxyphenyl) -3- [3 '- (2-hydroxy-3-tert-pentylaminopropoxy) -4'-methoxyphenyl] -1-propanone acetate, m.p .: 119-120 0 C.
34. 1-(2-Methoxyphenyl)-3-[3'-(2-hydroxy-3-n-propylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid,34. 1- (2-methoxyphenyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride,
Fp.: 141,5-1430C.Mp: 141.5-143 0 C.
35. 1-(2-Methoxyphenyl)-3-[3'-(2-hydroxy-3-tert.-butyland.nopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid,35. 1- (2-methoxyphenyl) -3- [3 '- (2-hydroxy-3-tert.butyland.nopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride,
Fp.: 166,5-167°C.Mp: 166.5-167 ° C.
36. 1- (4-Methylphenyl)-3- [3'-(2-hydroxy-3-tert.-pentylaminopropoxy)-4·-me thoxypheny1]-1-propanon-hydrochlorid, Fp.: 107,5-109,50C.36. 1- (4-Methylphenyl) -3- [3 '- (2-hydroxy-3-tert-pentylaminopropoxy) -4m-thoxyphenyl] -1-propanone hydrochloride, m.p .: 107.5-109 , 5 0 C.
37. 1-{4-Methylphenyl)-3-[3'-(2-hydroxy-3-n-propylaminoprop-37. 1- {4-methylphenyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropanol)
oxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.; 108-1100C.oxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .; 108-110 0 C.
38. 1-(4-Methylphenyl) -·3- [3 '-(2-hydroxy-3-morpholinopropoxy) · 4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 117-119,50C.38. 1- (4-methylphenyl) - · 3- [3 '- (2-hydroxy-3-morpholinopropoxy) · 4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 117 to 119.5 0 C.
39. 1-(4-Methylphenyl) -3- [3'-(2-hydroxy-3-tert.-butylaminogQ propoxy )-4'-methoxyphenyl]-1-propanon-hydrochlorid,39. 1- (4-methylphenyl) -3- [3 '- (2-hydroxy-3-tert-butylaminogo-propoxy) -4'-methoxyphenyl] -1-propanone hydrochloride,
Fp.: 117- 119°C.Mp .: 117-119 ° C.
40. 1.(4-Methylphenyl)-3-[3'-(2-hydroxy-3-piperidinopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid,40. 1. (4-methylphenyl) -3- [3 '- (2-hydroxy-3-piperidinopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride,
Fp.: 138,5-1400C.Mp: 138.5-140 0 C.
41. 1-(4-Methylphenyl)-3-[3'-(2-hydroxy-3-cyclohexylaminopropoy.y) -4' -methoxyphenyl] -1-propanon-hydrochlorid, Fp.: 134-136°C.41. 1- (4-Methylphenyl) -3- [3 '- (2-hydroxy-3-cyclohexylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 134-136 ° C.
42. 1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-tert.-pentylaminopropoxy)-4'-methoxyphenyl]-i-propanon-hydrochlorid. Fp.: 117-118°C.42. 1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-tert-pentylaminopropoxy) -4'-methoxyphenyl] -i-propanone hydrochloride. Mp .: 117-118 ° C.
43. 1 - (2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-piperidinopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 119-1200C.43. 1 - (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-piperidinopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 119-120 0 C. ,
44. 1-(2,4,6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-n-propylaminopropoxy)-4'-methoxyphenyl]-1-propanon-oxalat.44. 1- (2,4,6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) -4'-methoxyphenyl] -1-propanone oxalate.
Fp.: 121-1220C.Mp .: 121-122 0 C.
45. 1-(2,4;6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-isopropylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 110-1110C.45. 1- (2,4; 6-trimethylphenyl) -3- [3 '- (2-hydroxy-3-isopropylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 110-111 0 C. ,
46. 1-(2,4/6-Trimethylphenyl)-3-[3'-(2-hydroxy-3-morpholinopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 154-155°C.46. 1- (2,4 / 6-Trimethylphenyl) -3- [3 '- (2-hydroxy-3-morpholinopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 154-155 ° C ,
47. 1-(2-Naphthyl)-3- [3 ' - (2-hydroxy-3-tert .-pentY."" aminopropoxy) 4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 130-1320C,47. 1- (2-Naphthyl) -3- [3 '- (2-hydroxy-3-tert-pentY. "" Aminopropoxy) 4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 130-132 0 C,
N 48. 1-(2-Naphthyl)-3-[3'-(2-hydroxy-3-n-propylaminopropoxy) 4'-methoxyphenyl]-1-propanon-hydrochlorid, Fp.: 142-143°C. N 48. 1- (2-Naphthyl) -3- [3 '- (2-hydroxy-3-n-propylaminopropoxy) 4'-methoxyphenyl] -1-propanone hydrochloride, m.p .: 142-143 ° C.
49. 1-(2-Naphthyl)-3-[3'-(2-hydroxy-3-isopropylaminopropoxy)-4'-methoxyphenyl]-1-propanon-hydrochlorid, Fo.: 133-135°C.49. 1- (2-Naphthyl) -3- [3 '- (2-hydroxy-3-isopropylaminopropoxy) -4'-methoxyphenyl] -1-propanone hydrochloride, mp 133-135 ° C.
50. 1-(3-Phenanthrenyl)-3-[31-(2-hydroxy-3-isopropylaminopropoxy)-phenyl]-1-propanon-hydrochlorid, Fp.: 140-1420C. . " ·50. 1- (3-phenanthrenyl) -3- [3 1 - (2-hydroxy-3-isopropylaminopropoxy) -phenyl] -1-propanone hydrochloride, m.p .: 140-142 0 C.. "·
1 51. 1-(3-Phenanthrenyl)-3-[3'-(2-hydroxy-3-n-propylamino-1 51. 1- (3-phenanthrenyl) -3- [3 '- (2-hydroxy-3-n-propylamino)
propoxy)-phenyl1-1-propanon-hydrochlorid, Fp.: 149-152°C.propoxy) -phenyl-1-propanone hydrochloride, m.p .: 149-152 ° C.
Claims (1)
Patentansprüche 4-2
claims
R und R zusammen mit dem sie verbindenden Stickstoffatom,1 2
R and R together with the nitrogen atom connecting them,
in der R , R und η die vorstehend angegebene Bedeutung haben, mit einem Amin der allgemeinen Formel III3 4
in which R, R and η have the abovementioned meaning, with an amine of the general formula III
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP87109016A EP0296265A1 (en) | 1987-06-23 | 1987-06-23 | Aminopropanol derivatives of 3-(3-hydroxyphenyl)-1-propanone, process for their preparation and medicines containing these compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DD271108A5 true DD271108A5 (en) | 1989-08-23 |
Family
ID=8197085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DD88317034A DD271108A5 (en) | 1987-06-23 | 1988-06-22 | PROCESS FOR PREPARING AMINO-PROPANOL DERIVATIVES OF 3- (3-HYDROXYPHENYL) -1-PROPANONE COMPOUNDS AND THEIR SAEUREADDITIONAL SALTS |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP0296265A1 (en) |
JP (1) | JPS6426541A (en) |
KR (1) | KR890000401A (en) |
AR (1) | AR246246A1 (en) |
AT (1) | ATE68479T1 (en) |
CA (1) | CA1331877C (en) |
DD (1) | DD271108A5 (en) |
DE (2) | DE3865547D1 (en) |
DK (1) | DK342288A (en) |
ES (1) | ES2008640T3 (en) |
FI (1) | FI92482C (en) |
GR (2) | GR890300050T1 (en) |
HR (1) | HRP920925A2 (en) |
HU (1) | HU204502B (en) |
IL (1) | IL86813A (en) |
NO (1) | NO167975C (en) |
PT (1) | PT87793B (en) |
SU (1) | SU1634135A3 (en) |
YU (1) | YU120088A (en) |
ZA (1) | ZA884437B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994022842A1 (en) * | 1993-03-29 | 1994-10-13 | Basf Aktiengesellschaft | 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance |
JP2000512997A (en) | 1996-06-17 | 2000-10-03 | イーライ・リリー・アンド・カンパニー | Drug resistance and multidrug resistance modulators |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT66890B (en) * | 1976-08-21 | 1979-01-25 | Hexachimie | PROCESS FOR THE PREPARATION OF 1-ARYLOXY AMINO-3 PROPANOL-2 |
DE3226863A1 (en) * | 1981-09-18 | 1983-04-07 | Basf Ag, 6700 Ludwigshafen | AMINOPROPANOL DERIVATIVES OF 2-HYDROXY-SS-PHENYL-PROPIOPHENONES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC AGENTS CONTAINING THEM |
US4540697A (en) * | 1982-09-09 | 1985-09-10 | Basf Aktiengesellschaft | Aminopropanol derivatives of 2-hydroxy-β-phenyl-propiophenones, pharmaceutical compositions and use |
-
1987
- 1987-06-23 EP EP87109016A patent/EP0296265A1/en not_active Withdrawn
-
1988
- 1988-06-21 IL IL86813A patent/IL86813A/en not_active IP Right Cessation
- 1988-06-22 DD DD88317034A patent/DD271108A5/en not_active IP Right Cessation
- 1988-06-22 CA CA000570097A patent/CA1331877C/en not_active Expired - Fee Related
- 1988-06-22 FI FI883001A patent/FI92482C/en not_active IP Right Cessation
- 1988-06-22 ZA ZA884437A patent/ZA884437B/en unknown
- 1988-06-22 PT PT87793A patent/PT87793B/en not_active IP Right Cessation
- 1988-06-22 JP JP63154577A patent/JPS6426541A/en active Granted
- 1988-06-22 KR KR1019880007508A patent/KR890000401A/en not_active Application Discontinuation
- 1988-06-22 HU HU883183A patent/HU204502B/en not_active IP Right Cessation
- 1988-06-22 DK DK342288A patent/DK342288A/en not_active Application Discontinuation
- 1988-06-22 NO NO882771A patent/NO167975C/en unknown
- 1988-06-22 AR AR88311194A patent/AR246246A1/en active
- 1988-06-22 SU SU884355989A patent/SU1634135A3/en active
- 1988-06-22 YU YU01200/88A patent/YU120088A/en unknown
- 1988-06-23 DE DE8888110034T patent/DE3865547D1/en not_active Expired - Fee Related
- 1988-06-23 DE DE3821250A patent/DE3821250A1/en not_active Ceased
- 1988-06-23 ES ES198888110034T patent/ES2008640T3/en not_active Expired - Lifetime
- 1988-06-23 EP EP88110034A patent/EP0297435B1/en not_active Expired - Lifetime
- 1988-06-23 AT AT88110034T patent/ATE68479T1/en active
-
1989
- 1989-05-25 GR GR89300050T patent/GR890300050T1/en unknown
-
1991
- 1991-12-02 GR GR91401885T patent/GR3003257T3/en unknown
-
1992
- 1992-10-02 HR HR920925A patent/HRP920925A2/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2649605C3 (en) | p-substituted 1-phenoxy-3-amino-2-propanols, process for their preparation and pharmaceuticals containing them | |
EP0075207B1 (en) | Aminopropanol derivatives of 2-hydroxy-beta-phenyl propiophenones, processes for their preparation and therapeutic agents containing them | |
EP0074014B1 (en) | 2-(2'-hydroxy-3'-(1,1,-dimethyl propylamino)-propoxy)-beta propiophenone, its addition salts, process for its preparation and medicaments | |
DE2807623A1 (en) | PYRROLIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME | |
DE2528147A1 (en) | AROMATIC KETONE, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE KETONE | |
AT390054B (en) | METHOD FOR PRODUCING NEW BENZOYL DERIVATIVES FROM ALIPHATIC CARBONIC ACIDS | |
DD271108A5 (en) | PROCESS FOR PREPARING AMINO-PROPANOL DERIVATIVES OF 3- (3-HYDROXYPHENYL) -1-PROPANONE COMPOUNDS AND THEIR SAEUREADDITIONAL SALTS | |
EP0027928B1 (en) | Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, their preparation and pharmaceutical compositions containing them | |
DE69302087T2 (en) | TRAZODONE ALKYL DERIVATIVES WITH CNS EFFECT | |
CH618433A5 (en) | ||
DE3030802C2 (en) | ||
DE2351281C3 (en) | Aminophenylethanolamine derivatives, their production and use | |
EP0152556B1 (en) | Aminopropanol derivatives of substituted 2-hydroxy-propiophenones, process for their preparation and therapeutic agents containing them | |
EP0030688B1 (en) | Piperidine derivatives of 3-hydroxy-thiophene-2-carboxylic acid esters, their preparation, and pharmaceutical preparations containing them | |
DE3876546T2 (en) | ETHANON OXIME. | |
DD271701A5 (en) | PROCESS FOR PREPARING AMINO-PROPANOL DERIVATIVES OF 3- (2-HYDRO-XYPHENYL) -1-PROPANONE COMPOUNDS AND THEIR SAEUREADDITIONAL SALTS | |
CH630058A5 (en) | METHOD FOR PRODUCING NEW DISUBSTITUTED PHENOLAETHERS OF 3-AMINO-2-HYDROXYPROPANE. | |
DE1695963A1 (en) | Cycloalkenamine-p-benzoquinone adducts and processes for their preparation | |
CH632750A5 (en) | METHOD FOR PRODUCING NEW PIPERAZINE DERIVATIVES. | |
EP0296592B1 (en) | Aminopropanol derivatives of 3-(2-hydroxyphenyl)-1-propanone, process for their preparation and medicines containing these compounds | |
DE3102597C2 (en) | ||
DE3404481A1 (en) | BASIC CYCLOAL CANONOXIMAETHER, METHOD FOR PRODUCING THE SAME AND THEIR USE | |
DE2513806A1 (en) | ALKYLSULFONYLPHENOXYPROPANOLAMINES, THE METHOD OF MANUFACTURING THEM AND THE AGENTS CONTAINING THEY | |
EP0043971B1 (en) | Indanoneoxyalkylpiperazine derivatives, the preparation thereof and pharmaceutical compositions containing the same | |
DE4000213A1 (en) | O-HYDROXY-SS- (1-NAPHTHYL) -PROPIOPHENONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE MEDICAMENT CONTAINING THESE COMPOUNDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENJ | Ceased due to non-payment of renewal fee |